Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track NBTX with free AI briefings, catalyst countdowns, and dilution alerts.

NBTX · Nanobiotix S.A.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$110.9M Cash on Hand
38.9mo Cash Runway
Follow NBTX by email Get an email when NBTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NBTX, unsubscribe in one click. Privacy

📣 What NBTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Hafnium Oxide-containing Nanoparticles NBTXR3 Locally-Advanced Non-Small Cell Lung Cancer Phase 1/2 · NCT07224152 Recruiting
NBTXR3 activated by Brachytherapy & IMRT Prostate Cancer Phase 1/2 · NCT02805894 Terminated
NBTXR3 activated by IMRT only Prostate Cancer Phase 1/2 · NCT02805894 Terminated

Also used in these trials (approved or third-party drugs, not NBTX's own candidates): Nivolumab, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NBTX holds $110.9M in cash and short-term investments and burns about $8.5M/quarter from operations, an estimated runway of 38.9 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NBTX files for a raise →

👥 Who Owns NBTX

Insiders Form 4 data not loaded yet Other 5%+ holders 17.3% Institutions (23 holders) 11.8% Public and other holders 70.9%
HolderTypeShares% of sharesAs of
Invus Public Equities, L.P. 5%+ holder (13G) 4,828,374 9.97% 2026-06-30
Qatar Investment Authority 5%+ holder (13G) 3,532,517 7.30% 2026-06-30

Share count 48,410,068 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full NBTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NBTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.